Table 1.

Summary of current Alzheimer’s disease tau-targeted immunotherapy clinical trials.

Antibody	Trial I.D.	Phase	Method	Epitope	Patients	Status	End point
AADvac-1	NCT02031198	I	Active	Synthetic tau peptide	Mild AD; 50–80 years old	Safe Complete	2018
	NCT02579252	II	Active	Synthetic tau peptide	PSP, Mild to moderate AD; 50–80 years	Promising Ongoing	2019
ABBV-8E12	NCT02880956	II	Passive	Extracellular, aggregated tau	Mild AD, MCI; 50–85 years	Ongoing	2021
BIIB092	NCT03352557	II	Passive	N-terminus of tau	MCI, Mild AD and PSP; 50–80 years	Ongoing	2020
RO71015705	NCT02820896	II	Passive	Abnormal tau species	Mild to moderate AD; 50–80 years	Ongoing	2020